Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Patrick Rômbola OzaniqueDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (Unesp), São José do Rio Preto 15054-000, SP, Brazil.
Alvaro Luiz HelenaDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (Unesp), São José do Rio Preto 15054-000, SP, Brazil.
Ralciane de Paula MenezesDepartment Microbiology, Institute of Biomedical Sciences, Federal University of Uberlândia (UFU), Umuarama 38405-320, MG, Brazil.
Daniela Silva GonçalvesDepartment Microbiology, Institute of Biomedical Sciences, Federal University of Uberlândia (UFU), Umuarama 38405-320, MG, Brazil.ORCID 0000-0002-1120-0644
Mariana Brentini SantiagoDepartment Microbiology, Institute of Biomedical Sciences, Federal University of Uberlândia (UFU), Umuarama 38405-320, MG, Brazil.ORCID 0000-0002-6060-379X
Guilherme DilarriDepartment of Biochemistry and Microbiology, Institute of Biosciences, São Paulo State University (Unesp), Rio Claro 13506-900, SP, Brazil.ORCID 0000-0003-2625-7392
Janaína de Cássia Orlandi SardiDental Research Division, Guarulhos University, Guarulhos 07023-070, SP, Brazil.ORCID 0000-0002-8500-2691
Henrique FerreiraDepartment of Biochemistry and Microbiology, Institute of Biosciences, São Paulo State University (Unesp), Rio Claro 13506-900, SP, Brazil.ORCID 0000-0002-9183-9420
Carlos Henrique Gomes MartinsDepartment Microbiology, Institute of Biomedical Sciences, Federal University of Uberlândia (UFU), Umuarama 38405-320, MG, Brazil.ORCID 0000-0001-8634-6878
Luis Octávio RegasiniDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (Unesp), São José do Rio Preto 15054-000, SP, Brazil.ORCID 0000-0001-8574-0670
Funding
CNPq 471129/2013-5; 306251/2016-7, 429322/2018/6 and 309957/2019-2Fapesp 2014/18330-0 and 2018/15083-2
6 · The paper itself
Abstract
Drug-resistant bacteria constitute a big barrier against current pharmacotherapy. Efforts are urgent to discover antibacterial drugs with novel chemical and biological features. Our work aimed at the synthesis, evaluation of antibacterial effects, and toxicity of licochalcone C (LCC), a naturally occurring chalcone. The synthetic route included six steps, affording a 10% overall yield. LCC showed effects against Gram-positive bacteria (MIC = 6.2-50.0 µg/mL),
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis, Antibacterial Effects, and Toxicity of Licochalcone C. · full record | OpenQuestion